CN115485288A - 免疫调节剂 - Google Patents

免疫调节剂 Download PDF

Info

Publication number
CN115485288A
CN115485288A CN202180033390.0A CN202180033390A CN115485288A CN 115485288 A CN115485288 A CN 115485288A CN 202180033390 A CN202180033390 A CN 202180033390A CN 115485288 A CN115485288 A CN 115485288A
Authority
CN
China
Prior art keywords
alkyl
acceptable salt
compound
subject
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180033390.0A
Other languages
English (en)
Chinese (zh)
Inventor
汪涛
张钟兴
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of CN115485288A publication Critical patent/CN115485288A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CN202180033390.0A 2020-03-16 2021-03-16 免疫调节剂 Pending CN115485288A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062989940P 2020-03-16 2020-03-16
US62/989,940 2020-03-16
PCT/US2021/022474 WO2021188480A1 (en) 2020-03-16 2021-03-16 Immunomodulators

Publications (1)

Publication Number Publication Date
CN115485288A true CN115485288A (zh) 2022-12-16

Family

ID=75539903

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180033390.0A Pending CN115485288A (zh) 2020-03-16 2021-03-16 免疫调节剂

Country Status (6)

Country Link
US (1) US20230183292A1 (https=)
EP (1) EP4121442A1 (https=)
JP (1) JP2023517736A (https=)
KR (1) KR20220155332A (https=)
CN (1) CN115485288A (https=)
WO (1) WO2021188480A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024149369A1 (zh) * 2023-01-13 2024-07-18 苏州慧疗生物医药科技有限公司 甾体化合物、制备方法及其脂质纳米颗粒、药物组合物

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022221284A2 (en) * 2021-04-12 2022-10-20 Bristol-Myers Squibb Company Cyclic peptide immunomodulators
KR20230044603A (ko) * 2021-09-27 2023-04-04 (주) 테라베스트 약물 이합체를 포함하는 나노입자 및 이의 용도

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105209479A (zh) * 2013-03-15 2015-12-30 百时美施贵宝公司 Pd-1/pd-l1和cd80(b7-1)/pd-l1蛋白质/蛋白质相互作用的大环抑制剂
CN107428804A (zh) * 2015-03-18 2017-12-01 百时美施贵宝公司 免疫调节剂

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
MX9203291A (es) 1985-06-26 1992-08-01 Liposome Co Inc Metodo para acoplamiento de liposomas.
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
AU2002211863A1 (en) * 2000-10-06 2002-04-15 Xenoport, Inc. Bile-acid derived compounds for providing sustained systemic concentrations of drugs after oral administration
CZ2012326A3 (cs) * 2012-05-18 2013-10-30 Vysoká skola chemicko-technologická v Praze Konjugáty hydrazonu s kyselinou cholovou jako nová cytostatika
US9856292B2 (en) * 2014-11-14 2018-01-02 Bristol-Myers Squibb Company Immunomodulators
HRP20210644T8 (hr) * 2016-05-19 2021-06-25 Bristol-Myers Squibb Company Imunomodulatori za pet-snimanje
KR20220010535A (ko) * 2019-05-21 2022-01-25 브리스톨-마이어스 스큅 컴퍼니 면역조정제

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105209479A (zh) * 2013-03-15 2015-12-30 百时美施贵宝公司 Pd-1/pd-l1和cd80(b7-1)/pd-l1蛋白质/蛋白质相互作用的大环抑制剂
CN107428804A (zh) * 2015-03-18 2017-12-01 百时美施贵宝公司 免疫调节剂

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024149369A1 (zh) * 2023-01-13 2024-07-18 苏州慧疗生物医药科技有限公司 甾体化合物、制备方法及其脂质纳米颗粒、药物组合物

Also Published As

Publication number Publication date
JP2023517736A (ja) 2023-04-26
EP4121442A1 (en) 2023-01-25
KR20220155332A (ko) 2022-11-22
WO2021188480A1 (en) 2021-09-23
US20230183292A1 (en) 2023-06-15

Similar Documents

Publication Publication Date Title
US12403174B2 (en) Immunomodulators
CN114929714A (zh) 用于治疗癌症和感染性疾病的作为pd-l1抑制剂和免疫调节剂的大环肽
CN114641480A (zh) 作为pd-l1抑制剂和免疫调节剂用于治疗癌症和感染性疾病的大环肽
CN115485288A (zh) 免疫调节剂
CN114555627A (zh) 免疫调节剂
CN115916340A (zh) 免疫调节剂
EP4225774B1 (en) Macrocyclic immunomodulators
US12421278B2 (en) Immunomodulators
EP4225775B1 (en) Dimeric milla immunomodulators
WO2022221284A2 (en) Cyclic peptide immunomodulators
WO2022072797A1 (en) Macrocyclic peptide boronate immunomodulators
CN117157307A (zh) 环肽免疫调节剂

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination